* Address correspondence to:
Jie Wang, M.D., Ph.D., State Key Laboratory of Molecular Oncology,
Department of Medical Oncology, National Cancer Center/National Clinical
Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical
Sciences & Peking Union Medical College, Beijing, China, 100021,
Beijing, China. zlhuxi@163.com; Tel: +86-13910704669
Hua Bai, M.D., Ph.D., State Key Laboratory of Molecular Oncology,
Department of Medical Oncology, National Cancer Center/National Clinical
Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical
Sciences & Peking Union Medical College, Beijing, China, 100021,
Beijing, China. huabaihb@sina.com; Tel: +86-13810095769
Abstract
Lung cancer is the most common cancer and a leading cause of death from
cancer in men and women in the world. Epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are considered as the first-line
treatment of EGFR mutated NSCLC. However, almost all patients eventually
develop acquired resistance to EGFR-TKIs, with a median PFS of 9-14
months. With the development of immunotherapy, people realize that the
interaction between tumor immune microenvironment (TIME) and tumor cells
can also affect EGFR-TKIs treatment. TIME contains a variety of elements
and previous researches of TIME in EGFR-TKIs therapy on NSCLC are
decentralized. Here, we review the characteristics of TIME in NSCLC from
EGFR-TKIs therapy and its role in TKIs resistance.